Prescription drug prices in America remain high, but a federal program has quietly saved patients and safety-net healthcare organizations enormous sums since 1992. A 340B pharmacy dispenses medications purchased at deeply discounted prices under the federal 340B Drug Pricing Program, with participating providers either passing those savings on to patients or reinvesting them in community health services. If you receive care at a qualifying facility, you may already be eligible for lower prices without realizing it. This article explains how the program works, who qualifies, and the significant disputes now reshaping it. It is general information, not legal, medical, or financial advice.
What Is a 340B Pharmacy?
A 340B pharmacy is either an in-house pharmacy operated by a covered entity (such as a hospital or community health center) or a contract pharmacy that has an agreement with a covered entity to dispense 340B-priced drugs. The “340B” designation comes from Section 340B of the Public Health Service Act, added by the Veterans Health Care Act of 1992, which requires drug manufacturers that participate in Medicaid to sell covered outpatient medications at discounted prices to eligible healthcare organizations.
These discounts are substantial — often in the range of 25% to 50% off, and on some products considerably more. The Health Resources and Services Administration (HRSA), part of the U.S. Department of Health and Human Services, oversees the program and maintains a public database of registered covered entities and their associated pharmacies. Because exact discounts vary by drug and change over time, treat any specific percentage as a general estimate rather than a guarantee.
How the 340B Program Works
Drug manufacturers that want their products covered by Medicaid must also participate in 340B. They agree to sell covered outpatient drugs at or below the 340B “ceiling price,” which is calculated using a statutory formula based on the Average Manufacturer Price minus the Medicaid unit rebate amount. HRSA publishes ceiling prices through a secure pricing system available to covered entities.
Covered entities purchase drugs at these reduced prices and dispense them to eligible patients. An entity may operate its own pharmacy or contract with retail pharmacies to fill prescriptions at 340B pricing. The difference between the discounted acquisition cost and what the entity is reimbursed (by insurance or the patient) generates margin that the statute intends to be used to stretch scarce federal resources — funding sliding-fee-scale programs, charity care, and expanded clinical services. How much of that benefit reaches an individual patient at the counter depends on the entity’s own policies.
Who Qualifies to Use a 340B Pharmacy?
You do not need to meet a separate income test to fill prescriptions at a 340B pharmacy. Eligibility depends on where you receive your healthcare. If you are a patient of a 340B-covered entity — meaning you have an established relationship with a qualifying hospital, community health center, or clinic — you may be eligible for 340B-priced prescriptions.
Covered entities include Federally Qualified Health Centers (FQHCs), Ryan White HIV/AIDS Program grantees, disproportionate share hospitals (DSH hospitals), children’s hospitals, critical access hospitals, sole community hospitals, rural referral centers, and certain specialized clinics such as family planning, tuberculosis, and hemophilia treatment centers. Importantly, not every patient at a covered entity automatically receives 340B pricing at the register. The entity sets its own policies about which patients benefit from the discounted drugs and how the savings are distributed.
Finding a 340B Pharmacy Near You
HRSA maintains an online database called the Office of Pharmacy Affairs Information System (OPAIS) at HRSA.gov/opa. You can search for registered covered entities by state, city, or ZIP code. Each listing shows the entity’s registered contract pharmacies where 340B prescriptions may be filled.
Community health centers are among the most accessible 340B covered entities. There are roughly 1,400 FQHC organizations across the country operating thousands of sites and serving well over 30 million patients. If you do not currently receive care at an FQHC, you can establish yourself as a patient. Most FQHCs offer sliding-fee-scale charges based on income, and many pass along drug discounts to patients regardless of insurance status — though, again, specific pricing depends on the center’s policies, so ask directly.
Savings Examples
Where savings are passed to the patient, the effect at a 340B pharmacy can be dramatic. A brand-name medication that retails for several hundred dollars a month might cost a fraction of that through a 340B program. Specialty medications for conditions like HIV, hepatitis C, and cancer often see the largest absolute discounts. These are illustrative examples, not quoted prices — your actual cost depends on the drug, your coverage, and the covered entity’s dispensing and pricing policies.
The discounts apply to covered outpatient drugs broadly, not just generics, which is why the program is especially valuable for patients taking expensive brand-name or specialty medications with no generic equivalent. If you currently use prescription discount cards or GoodRx coupons, it is worth comparing those prices with what a 340B pharmacy offers, since 340B pricing can be lower — but compare case by case rather than assuming.
340B Pharmacy vs. Other Savings Programs
The 340B program differs from other prescription savings options in important ways. Unlike manufacturer patient assistance programs (such as those from Novo Nordisk or AbbVie), 340B does not require you to be uninsured. Patients with commercial insurance, Medicare, and Medicaid may all be able to fill prescriptions at 340B pharmacies, subject to program rules such as the prohibition on “duplicate discounts” with Medicaid.
Compared to Medicare Extra Help, which is limited to Medicare Part D beneficiaries, 340B is tied to being a patient of a covered entity. The two can sometimes work together: a Medicare beneficiary who receives care at an FQHC may use Extra Help for Part D benefits while the covered entity accesses 340B pricing on the back end. For a comprehensive view of savings strategies, see our healthcare costs guide, and for the policy context, our healthcare policy guide.
Controversies, Disputes, and Limitations
The 340B program has grown enormously and is now one of the most contested areas in U.S. drug-pricing policy. By one widely cited estimate, discounted 340B purchases reached roughly $66 billion in 2023, up sharply from about $16 billion in 2016, and roughly a third of U.S. hospitals participate. That scale has intensified a long-running debate over whether the savings are being used as Congress intended.
Contract-pharmacy restrictions. Beginning in 2020, a number of drug manufacturers moved to restrict or condition 340B pricing on drugs dispensed through contract pharmacies, arguing the practice had expanded far beyond the statute’s original design. HRSA challenged several of these restrictions, but federal appellate courts (including the Third and D.C. Circuits) largely sided with manufacturers, holding that Section 340B does not clearly require delivery to an unlimited number of contract pharmacies. These rulings can limit where you are able to fill 340B prescriptions at certain retail chains, so check with your covered entity about which pharmacies currently honor its 340B agreements.
The rebate-model debate. More recently, several manufacturers have proposed replacing the up-front discount with a “rebate model,” in which covered entities would pay full price and later receive a rebate after proving a claim was 340B-eligible. Supporters say it would curb duplicate discounts and improve program integrity; covered entities and safety-net advocates warn it would create cash-flow burdens and administrative hurdles that could shrink the savings that fund patient care. As of early 2026, HRSA had resisted broad manufacturer-imposed rebate schemes while exploring limited pilots, and the issue was the subject of active litigation and policy debate. This area is changing quickly — verify the current status before relying on it.
State laws. Many states have passed “contract pharmacy protection” laws seeking to bar manufacturers from restricting 340B dispensing, and these have themselves been litigated with mixed results. The legal landscape differs by state.
Oversight and scope limits. Government watchdogs, including the U.S. Government Accountability Office, have reported that oversight of how 340B savings are used has been limited and that not all savings clearly reach patients directly; HRSA has responded over time with additional auditing and guidance. Separately, the program does not cover inpatient drugs, vaccines purchased through certain other federal programs, or drugs used in clinical trials — only qualifying outpatient prescriptions dispensed by or on behalf of a covered entity.
Frequently Asked Questions
Do I need to be uninsured to use a 340B pharmacy?
No. Patients with private insurance, Medicare, Medicaid, and no insurance can all potentially fill prescriptions at a 340B pharmacy. Eligibility depends on having a patient relationship with a 340B-covered entity, not on your insurance status, though program rules govern how discounts interact with Medicaid and Medicare.
How do I know if my pharmacy participates in 340B?
Ask your healthcare provider or check the HRSA OPAIS database at HRSA.gov/opa. The database lists registered covered entities and their contract pharmacies. Many community health centers also have on-site pharmacies that dispense 340B drugs directly. Because manufacturer restrictions can change which contract pharmacies are usable, confirm current participation with the covered entity.
Are all medications available at 340B prices?
The 340B program covers most FDA-approved outpatient drugs from participating manufacturers, but not every drug at every pharmacy will be available at 340B pricing. Some manufacturers have restricted 340B sales at contract pharmacies. Your covered entity can confirm which medications are currently available at discounted prices.
Will I personally see a lower price at the counter?
Not always. Some covered entities pass 340B savings directly to patients through low cash prices or sliding-fee programs; others use the margin to fund broader services. Ask the specific entity how it handles 340B pricing for patients like you.
Can I use a 340B pharmacy if I have Medicare Part D?
Yes, but the interaction between 340B and Part D is complex. Your Part D plan typically pays first, and the 340B discount applies to the covered entity’s acquisition cost. You may not always see a direct out-of-pocket savings at the pharmacy counter, but the covered entity may reinvest the 340B margin into patient services.
Access 340B Savings Today
If you are struggling with prescription costs, a 340B pharmacy could be an option you have overlooked. Start by visiting HRSA.gov/opa to find covered entities in your area, establish care at a Federally Qualified Health Center or qualifying hospital, and ask specifically how their pharmacy handles 340B pricing for patients. Combined with programs like Extra Help Medicare and prescription discount cards, 340B access can meaningfully reduce what some patients pay for medications — but confirm the current rules and pricing, because the program’s contract-pharmacy and rebate policies are actively changing.
Disclaimer: This article is for general informational purposes only and is not legal, medical, financial, or policy advice. The 340B Drug Pricing Program is complex, governed by federal statute and HRSA guidance, and is the subject of ongoing litigation and rapidly changing rules on contract pharmacies and rebate models. Discount amounts, eligibility, and whether savings reach an individual patient vary by covered entity and drug. Verify current program details with HRSA and directly with the covered entity, and consult a qualified professional about your specific situation.
Sources
- HRSA Office of Pharmacy Affairs — 340B Drug Pricing Program overview and OPAIS database (hrsa.gov/opa)
- Public Health Service Act, Section 340B; Veterans Health Care Act of 1992
- KFF — 340B Drug Pricing Program explainers, including program-size estimates (approximately $66 billion in 2023) and the rebate-model debate
- U.S. Government Accountability Office (GAO) — reports on 340B oversight and program integrity
- Federal appellate litigation on manufacturer contract-pharmacy restrictions (Third Circuit and D.C. Circuit decisions) and related state contract-pharmacy laws